drugset / Trial / NCT02757417
Intravenous Sodium Fluorescein Versus Oral Phenazopyridine for Ureteral Patency
Withdrawn
University Hospitals Cleveland Medical Center
Alex Soriano · collabGraham Chapman · collabMegan Billow · collabSangeeta Mahajan · collabSherif El-Nashar · collab
RandomizedParallel-groupOpen-labelDiagnostic
Summary
To determine the safety profile of sodium fluorescein in women undergoing cystoscopy during gynecologic surgery. To determine if either oral phenazopyridine or sodium fluorescein result in shorter cystoscopy times.
Timeline
- Start
- 2016-07
- Primary completion
- 2018-01
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Phenazopyridine | Small molecule | 200 mg | Oral |
| Comparator | Sodium Fluorescein | Diagnostic / imaging agent | 25 mg | Intravenous |
Indications
No indication recorded.